Vietnam’s Mekong Capital has exited its 25% stake in domestic pharmaceuticals company Traphaco for about $64.5 million. It represents a gross return multiple of 6.3x for the investment.
Mekong invested Traphaco via its Vietnam Azalea Fund (VAF), initially taking a 5% stake in 2007 and becoming the company’s first foreign shareholder. VAF subsequently increased its stake through several...
Even if pan-Asian buyout firms aren't actively pursuing investments in internet-related businesses, they cannot ignore the potential disruptive impact of these technologies on other portfolio companies
Mekong Capital's 6.3x return on its investment in Vietnam-based pharmaceuticals player Traphaco involved turning the company's distribution model on its head, as well as supporting expansion and improving governance
China Renaissance has added dedicated healthcare and mezzanine debt strategies to its existing growth-stage private equity offering as part of efforts to more than treble its assets under management (AUM) over the next three years.
China Venture Capital Fund, a VC vehicle backed by the Chinese government, and ChinaEquity Group have jointly led a RMB670 million ($101 million) round for 3D Medicines, which focuses on personalized diagnostics and treatment for cancer.